Fixed drug eruption induced by topical olopatadine ophthalmic solution

Hum Exp Toxicol. 2012 Dec;31(12):1292-4. doi: 10.1177/0960327112440112. Epub 2012 Apr 24.


Fixed drug eruption (FDE) usually develops after oral administration and is described as a cutaneous reaction recurring at the same location each time the drug is taken. Olopatadine is both a H1 histamine receptor antagonist and a mast cell stabilizer, indicated for the treatment of allergic conjunctivitis. Here, we report a 14-year-old male patient who developed FDE localised on the lateral side of periorbital rim bilaterally, whilst applying olopatadine 0.1% ophthalmic solution for the treatment of allergic conjunctivitis. As far as we know, FDE due to olopatadine has not been previously reported in the literature. We deem it appropriate to report this case because FDE that results from the application of topical drugs is a rare event in the literature.

Publication types

  • Case Reports

MeSH terms

  • Administration, Topical
  • Adolescent
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Conjunctivitis, Allergic / complications
  • Conjunctivitis, Allergic / drug therapy
  • Dibenzoxepins / adverse effects*
  • Drug Eruptions / etiology*
  • Drug Eruptions / pathology
  • Humans
  • Male
  • Olopatadine Hydrochloride
  • Ophthalmic Solutions / adverse effects*
  • Orbit / drug effects
  • Orbit / pathology
  • Orbital Diseases / chemically induced*
  • Orbital Diseases / pathology


  • Anti-Inflammatory Agents, Non-Steroidal
  • Dibenzoxepins
  • Ophthalmic Solutions
  • Olopatadine Hydrochloride